Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • ams4900 ams4900 Sep 13, 2012 11:22 AM Flag

    The battle for Middle Earth is about to begin

    The clock is ticking patents are in place with new ones coming as Amarin opens the use via different Patents. The medication will IMHO beat Lovaza for volume the first year out based on that alone.
    Talked to a Druggist (1) about costs of Lovaza as from a user point of view. He has ~250 patients using the Lovaza each month 75% are paying $280 dollars a month as their provider does not cover. If it is covered 18.00.

    GSK is rumored to be looking for heavy amount of finance with big investors. I would think that in their business model for CAPEX it would be a motivator to the ones that hold notes on GSK that we need some money or we lose 2 bil in sales with-in one year.

    Also GSK has the 3/4 billion purchase of Sirtuis Pharm (Googlr Sirt 101 and Dr Sinclair) that has gone into hibernation.
    The drug hit a dead end as absorption of resveratrol was inhibitive of keeping enough in the human system and it did not sequence the human gene as did the studys with rats.
    Last study I read is a EPA pure showed solubility and efficacy improvement.

    Just sayin....

    PS Joe if your going to play poker...don't say (no matter what you are thinkin) bring up going alone til it's time to do just that

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The clock is ticking patents are in place with new ones coming as Amarin opens the use via different Patents. The medication will IMHO beat Lovaza for volume the first year out based on that alone.
      Talked to a Druggist (1) about costs of Lovaza as from a user point of view. He has ~250 patients using the Lovaza each month 75% are paying $280 dollars a month as their provider does not cover. If it is covered 18.00.

      GSK is rumored to be looking for heavy amount of finance with big investors. I would think that in their business model for CAPEX it would be a motivator to the ones that hold notes on GSK that we need some money or we lose 2 bil in sales with-in one year.

      Also GSK has the 3/4 billion purchase of Sirtuis Pharm (Google Sirt 101 and Dr Sinclair) that has gone into hibernation.
      The drug hit a dead end as absorption of resveratrol was inhibitive of keeping enough in the human system and it did not sequence the human gene as did the studys with rats.
      Last study I read is a EPA pure showed solubility and efficacy improvement.

      NO COMPANY IS OUT OF THE BO COMING

      Just sayin....

      PS Joe if your going to play poker...don't say (no matter what you are thinkin) bring up going alone til it's time to do just that

    • Deja vu
      on this bump

 
AMRN
2.46+0.15(+6.49%)Jun 30 4:00 PMEDT